Acticor Biotech, a clinical-stage biotechnology company, announced the enrollment of the first patient in the USA in its phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
This first US patient was enrolled at the CHI Memorial Stroke and Neuroscience Center, Chattanooga, Tennessee, by Dr. Ruchir A. Shah, MD, neurologist who said:
